Abstract:Objective:Since originally establishing genetic linkage at chromosome 9p21.3-9p21.1 in families with concomitant frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) we have been actively genotyping one of the largest North American ALS and ALS/FTD cohorts for the C9orf72 (G4C2) expansion mutation to determine whether the frequency of the mutation is similar to other reports.Background:A hexanucleotide (G4C2) repeat expansion mutation on Chromosome 9 open reading frame 72 (C9orf72; C9) is currently identified as the most common cause of ALS and FTD. C9(+) expansion carriers are defined as having ≥30 (G4C2) repeats that generate a typical saw-tooth electropherogram pattern following repeat primed-polymerase chain reaction (RP-PCR) analysis.Methods:A cohort of patients with FALS or SALS, with and without FTD, and neurologically normal controls were screened for the C9 expansion mutation using the RP-PCR method.Results:We identified ~50[percnt] FALS and ~5[percnt] SALS cases as C9(+) mutations. While we found no statistical difference in gender distribution, ethnicity or age at onset when compared with C9(-) carriers, we found that disease onset was more likely to be bulbar or cognitive, and disease duration was shorter in C9(+) carriers compared with C9(-) carriers. Interestingly, we also found that ~40[percnt] of our C9(+) cases generated a previously unreported atypical electropherogram pattern that is characterized by a series (27) of low SI that requires manipulation of the SI range for adequate detection. Moreover, affected subjects with atypical expansion patterns were predominately Caucasians and had a longer disease duration than individuals with typical saw-tooth expansion patterns in our SALS cohort.Conclusions:Variances in the expansion pattern may serve as markers for disease with unique clinical features reflecting the phenotypic variability observed in ALS and FTD patients. Its relevance to pathogenic mechanisms is being explored. Disclosure: Dr. Lowry has nothing to disclose. Dr. Yan has nothing to disclose. Dr. Feiz has nothing to disclose. Dr. Yang has nothing to disclose. Dr. Kinsley has nothing to disclose. Dr. Siddique has nothing to disclose. Dr. Deng has nothing to disclose. Dr. Siddique has nothing to disclose.

Isoform Specific Antibodies Reveal Distinct Subcellular Localizations of C9orf72 in Amyotrophic Lateral Sclerosis.

Validated assays for the quantification of C9orf72 human pathology

Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs

Myeloid and lymphoid expression of C9orf72 regulates IL-17A signaling in mice

Cerebellar C9ran Proteins Associate with Clinical and Neuropathological Characteristics of C9ORF72 Repeat Expansion Carriers

The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway

Unaffected mosaic C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression.

Comprehensive Preclinical Evaluation of Human-Derived Anti-Poly-ga Antibodies in Cellular and Animal Models of C9ORF72 Disease

C9ORF72 Mutations in Neurodegenerative Diseases.

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

C9orf72 gene networks in the human brain correlate with cortical thickness in C9-FTD and implicate vulnerable cell types

Elevated Cerebrospinal Fluid Ubiquitin Carboxyl‐Terminal Hydrolase Isozyme L1 in Asymptomatic C9orf72 Hexanucleotide Repeat Expansion Carriers

C9orf72 regulates the unfolded protein response and stress granule formation by interacting with eIF2α

Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism

Unaffected mosaic <i>C9orf72</i> case

Toxic gain-of-function mechanisms in C9orf72 ALS-FTD neurons drive autophagy and lysosome dysfunction

Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Reduced C9ORF72 Function Exacerbates Gain of Toxicity from ALS/FTD-causing Repeat Expansion in C9orf72

The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS

Atypical Electropherogram Patterns are Observed Among C9orf72 (G4C2) Expansion Carriers in a Familial and Sporadic ALS and ALS/FTD North American Cohort Study (P5.056)

Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.